The 340B Drug Pricing Program lowers the cost of outpatient drugs to certain federal grant recipients. Comprehensive Hemophilia Treatment Centers that get a grant from the U.S. HRSA/MCHB can buy outpatient drugs for their patients at these discounted prices. Over half the HTCs in the U.S. — and nearly all in Region IX — have 340B programs.
The purpose of 340B
Stretch scarce Federal resources as far as possible
Reaching more eligible patients
Providing more comprehensive services
Use of 340B
[H.R. Rep. No 102-384, at 12 (1992)]. HRSA/MCHB requires 340B program income to be used to “further eligible project and program objectives.”
This 7 minute video describes the importance of the federal 340B discount drug program to people with genetic bleeding disorders.